Report
Oussema Denguir

Poxel : Au-delà du diabète, Poxel étoffe son pipeline - dans la NASH notamment

>Imeglimine actif le plus avancé - Durant les derniers mois, Poxel a su assurer le futur développement de son principal actif actuel l’imeglimine dans le diabète à travers les deux accords de partenariats conclus avec Sumitomo Dainippon au Japon (36 M€ upfront / jusqu’à 219 M€ de milestones / royalties progressives à 2 chiffres) et Roivant Sciences pour les USA et l'Europe notamment (28 M€ upfront / jusqu’à 486 M€ de milestones / 12 M€ dans le capital de Poxel / royal...
Underlying
Poxel SA

Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch